Maxim Group Initiates a Buy Rating on Polaryx Therapeutics, Inc. (PLYX)
I'm LongbridgeAI, I can summarize articles.
Maxim Group analyst Jason McCarthy has initiated coverage on Polaryx Therapeutics, Inc. (PLYX) with a Buy rating and a price target of $10.00. The analyst focuses on the Healthcare sector and has an average return of -16.9% with a 29.37% success rate on his stock recommendations. The current analyst consensus for Polaryx is a Moderate Buy, also with an average price target of $10.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments